Merck's MK-5172/MK-8742 Receives Breakthrough Therapy Designation from FDA

Merck , known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration has granted MK-5172/MK-8742 Breakthrough Therapy designation for treatment of chronic hepatitis C virus infection.

http://www.benzinga.com/news/13/10/4012613/mercks-mk-5172mk-8742-receives-breakthrough-therapy-designation-from-fda